Loading...
ORIC logo

ORIC Pharmaceuticals, Inc.NasdaqGS:ORIC Stok Raporu

Piyasa Değeri US$1.5b
Hisse Fiyatı
n/a
1Y45.8%
7D2.4%
1D2.3%
Portföy Değeri
​
Görünüm

ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC Stok Raporu

Piyasa değeri: US$1.5b

ORIC Pharmaceuticals (ORIC) Hisse Özeti

Klinik aşamada bir biyofarmasötik şirketi olan ORIC Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde kanserlerdeki direnç mekanizmalarına karşı koyacak tedavilerin keşfi ve geliştirilmesiyle ilgilenmektedir. Daha fazla detay

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 5.5% oranında düşmesi öngörülüyor

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda US piyasasına kıyasla dalgalı hisse senedi fiyatı


ORIC Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW466,456 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
466,456 investors already sharing narratives
View all narratives

ORIC Pharmaceuticals, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti ORIC Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$14.20
52 Haftanın En Yüksek SeviyesiUS$14.93
52 Haftanın En Düşük SeviyesiUS$7.23
Beta0.97
1 Aylık Değişim17.36%
3 Aylık Değişim70.67%
1 Yıllık Değişim45.79%
3 Yıllık Değişim56.22%
5 Yıllık Değişim-36.89%
Halka arzdan bu yana değişim-44.90%

Son Haberler & Güncellemeler

Seeking Alpha • Jul 21

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

Summary ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC’s $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat’s value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns. Enozertinib shows promising CNS activity in NSCLC; pivotal updates in 2H 2026 are crucial for confirming its competitive differentiation and registrable profile. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Seeking Alpha • Jul 21

ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Case

Summary ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, with full global rights and royalty-free economics. ORIC’s $419.7M cash position funds operations into 2H 2028, supporting pivotal trial readouts while minimizing dilution via strategic partnerships and disciplined capital allocation. Rinzimetostat’s value is enhanced by a unique royalty-free license and free darolutamide supply from Bayer, maximizing potential post-approval returns. Enozertinib shows promising CNS activity in NSCLC; pivotal updates in 2H 2026 are crucial for confirming its competitive differentiation and registrable profile. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 22

ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans

Summary ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for now but will need additional funding by late 2025 to support phase 3 trials. The company's valuation is high relative to its early-stage peers, but recent share price declines make it a "Hold" rather than a "Sell". Given the high risk and early data, I recommend a "Hold" rating unless you're highly risk-tolerant; the potential is strong but uncertain. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 27

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 02

ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data

Summary ORIC Pharmaceuticals' ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. ORIC-114 shows strong CNS penetration and promising results in brain metastasized NSCLC, with a significant market potential. ORIC-944, targeting prostate cancer, has shown encouraging efficacy and big pharma interest, but more data is needed. Despite promising early-stage data, ORIC remains in the high-risk phase 1 stage; more mature data is needed before committing. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 12

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analiz Makalesi • Aug 21

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 29

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Summary ORIC Pharmaceuticals is developing agents to address resistance to approved cancer therapies, trading at a premium due to recent announcements. The pipeline includes ORIC-114 targeting EGFR/HER2 mutations, ORIC-944 for prostate cancer, and ORIC-533 for multiple myeloma. Financially stable with a long cash runway, but early efficacy data and hype surrounding ORIC stock warrant caution in investing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 17

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Summary ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients. Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively. The company had cash of $331.5 million as of March 31st of 2024; Enough cash to fund its operations into late 2026. Read the full article on Seeking Alpha
Analiz Makalesi • May 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 13

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Summary ORIC Pharmaceuticals has reported positive preliminary results for three programs in its pipeline: ORIC-944, ORIC-114, and ORIC-533. ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first half of 2024 and provide a program update in mid-2024. The global prostate cancer market size is projected to surpass $27.51 billion by 2032. ORIC had $235 million in cash as of December 31st, 2023. It believes that it has enough cash on hand to fund its operations into 2026. Read the full article on Seeking Alpha
Analiz Makalesi • Jan 18

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Sep 27

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jun 14

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Jan 24

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ORIC is well-capitalized with Q2 cash position of $237.8M and valuation appears overly pessimistic at EV of negative $80M. ORIC is a Speculative Buy. Key risks include disappointing data for phase 1 readouts 1H 23, delays in the clinic and heavy competition in certain areas. Shares of ORIC Pharmaceuticals (ORIC) have fallen by over 80% since upsized IPO was priced at $16 in April of 2020. So far in 2022, share price has also experienced a dismal 80% decline. Back in March I sold my remaining shares for a 68% loss at $4.50 (still 50% higher than where they currently trade). However, I did highlight conviction-sized insider buying and reminded readers that I planned to revisit in a couple quarters when 2023 readouts were closer. As time has passed, I decided to check back in on the story and found the valuation to be incredibly pessimistic ($120M market capitalization versus estimated Q3 cash position of just over $200M). In other words, Mr. Market is stating that ORIC, with 3 clinical-stage programs in early phase 1b studies, is worth NEGATIVE $80M. These are not merely "me-too" assets, as their EGFR/HER2 exon-20 program is brain penetrant (can address CNS-metastases where approved agents lack activity). Likewise, the PRC2 program is targeting the EED subunit whereas predecessors have opted for the EZH2 subunit (plagued by tolerability issues) and management noted that certain subpopulations in prostate cancer could allow for accelerated approval should data warrant. The above to say, with the usual caveats, that I think we should dig deeper as the company would seem to be worth more than NEGATIVE $80M. Chart Finviz Figure 1: ORIC weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, the decline from highs above $40 to current $3 share price is quite sickening (appears as if the company has "flat-lined" and is a shell of its former self). Despite looking like a shell company, there is still a lot going on under the hood (three phase 1 studies with readouts coming 1H 23) and so my initial suggestion for risk-tolerant investors would be to accumulate a small to modestly sized position at current levels ahead of these events. Given the current macro environment and headwinds to both risk assets as well as biotech sector, purchases could be spaced out over a period of months (or even quarters) instead of all at once. Overview Founded in 2014 with headquarters in San Francisco (78 employees), ORIC Pharma currently sports enterprise value of ~NEGATIVE $80M and estimated Q3 cash position of $200M providing them operational runway into 2H 2024. Here are my notes from September's Wainwright webcast which provides an excellent overview of current operations: ORIC= Overcoming Resistance in Cancer and encompasses their mission statement. Pipeline is broad and consists of potential first-in-class drug candidates and they have 3 ongoing phase 1b single-agent studies focused on validated targets followed by a pipeline of preclinical programs (both internally sourced as well as via external business development). They ended Q2 with $238M in cash with expected operational runway into 2H 24 (over a year after 3 data readouts expected in the first half of 2023). Corporate website Figure 2: Pipeline (Source: corporate website) Leadership team is highly experienced, starting with preclinical research discovery capabilities led by CSO and team that previously worked together at Genentech. They also possess full development, clinical and regulatory capabilities led by CMO and team that worked together previously at Ignyta and Aragon. Finally, they have extensive business development and strategic inlicensing capabilities via a team that worked together previously at Medivation and Ignyta. Successful oncology business models of the past several years tended to focus on building pipeline via internal discovery efforts or via business development. However, ORIC has been able to take a "source agnostic" approach to building the pipeline where the best molecule wins (whether internally developed or externally sourced). ORIC-533 is an oral bioavailable CD73 inhibitor discovered internally, whereas ORIC-114 was sourced from South Korean company Voronoi in October of 2020 and ORIC-944 from Mirati Therapeutics in July of 2020. They have 3 ongoing phase 1b studies. Bar is set high for differentiation versus competitors. Lastly, newest program is first-in-class PLK4 inhibitor in lead optimization stage. Starting with ORIC-533, they believe the molecule is differentiated on two fronts (both preclinically as well as via clinical development plan as a single agent in multiple myeloma). Preclinically versus other small and large molecule inhibitors of CD73 (as well as A2A receptor programs), ORIC-533 showed higher potency in multiple models. Also, 533 differentiates in a high adenosine or high AMP environment as well (important given high levels of adenosine typically seen in tumor microenvironment). For multiple myeloma, last year they showed a variety of preclinical results supporting potential as a single agent followed by combination trials pending single agent activity. Key takeaway from data presented last year (ex vivo autologous patient level) was that ORIC-533 achieved 40% lysis in these models (compared favorably to other approved agents in same models like lenalidomide and bortezomib). In the current phase 1 study they are enrolling late-line MM patients (triple and quad-refractory) starting as single agent. If there is even modest activity (sounds like the bar is not being set high), they'd move into multiple combination cohorts. As far as they know, ORIC-533 is the only CD73 inhibitor being tested as a single agent in multiple myeloma. Wainwright webcast Figure 3: Activity of ORIC-533 in MM comparable to standard of care therapies (Source: Wainwright presentation) Moving on to ORIC-114, this is a brain-penetrant EGFR/HER2 exon-20 program. Management prioritized finding a molecule selective for exon-20 insertion mutations over wild type (been a challenge for other players in the field). Second, they wanted to see CNS activity given prevalence of CNS metastases in this population. This molecule was specifically optimized across selectivity and brain penetration (exquisitely clean). Two currently approved agents for exon-20 have tolerability issues as well as lack of CNS activity. For ORIC-144, potent tumor regression has been observed in multiple non small cell lung cancer EGFR insertion models without significant weight loss. Head-to-head preclinical studies were also performed and 144 compared favorably in terms of efficacy and selectivity/signs of potential toxicities. Wainwright webcast Figure 4: In vivo efficacy for ORIC-144 compares favorably to competitors (Source: Wainwright presentation) The most important thing to highlight is CNS activity, as leading agents don't address CNS mets (35% to 40% of these patients develop CNS mets). In vivo data versus TAK-788 and osimertinib (clinically active CNS compound) showed superiority for ORIC-144. HER2 is another indication of interest for ORIC-144, and benchmark data versus Seagen's (SGEN) HER2 inhibitor tucatinib demonstrated antitumor activity in intracranial HER2+ breast cancer model (outperforming tucatinib). This is important as 50% of HER2+ breast cancer patients develop brain metastases. Phase 1b study is enrolling patients with advanced solid tumors who have either EGFR or HER2 exon-20 alterations or HER2 amplification or overexpression. Unlike competitor phase 1 studies, they are allowing patients with active CNS mets (treated or untreated but asymptomatic). CEO notes that amivantamab from JNJ is a great drug, but the big difference is again they are a large molecule and excluding patients with CNS mets. Wainwright webcast Figure 5: Superior efficacy for ORIC-144 in intracranial EGFR mutant models (Source: Wainwright presentation) Lastly, for allosteric PRC2 inhibitor ORIC-944, CEO notes that the PRC2 complex is a validated target with approved agents for epithelial sarcoma and follicular lymphoma. There are two druggable subunits for this complex, with most companies approaching it via EZH2 (associated with poor tolerability or PK limitations). There is only one other EED inhibitor in oncology (MAK683 from Novartis). Work done by Mirati comparing ORIC-944 to tazmetostat in DLBCL shows the former outperforming the latter by a wide margin. In androgen-resistant prostate cancer models, ORIC-944 showed good tumor growth inhibition (79% to 86% whereas competitors have seen 40% to 45% TGI). Per CEO, phase 1 study is progressing well (enrolling metastatic prostate cancer patients that have failed one or more AR modulators and up to 2 bouts of chemotherapy). These are later line patients lacking great options available, and goal is looking at safety, PK and selection of recommended phase 2 dose (sounds like they are expecting less in terms of early activity). Interestingly, they aim to see subsets of patients or potential biomarkers that would allow for accelerated approval in certain (smaller but still sizeable) populations. Wainwright webcast Figure 6: Strong single agent activity observed for ORIC-944, significantly better than blockbuster drug enzalutamide (Source: Wainwright presentation) PLK4 inhibitor program is in lead optimization, with the rationale being that cells with TRIM37 amplification require PLK4 function for growth and survival. TRIM37 amplification occurs in 20% of breast cancer and 50% of neuroblastoma and has been associated with early relapse and poor prognosis. This represents a synthetic lethality approach. Other Information For the second quarter of 2022, the company reported cash and equivalents of $237.8M contrasting favorably to R&D expenses of $13.8M and G&A expenses of $6.9M. Management is guiding for operational runway into 2H 2024, which seems reasonable to my eyes. Accumulated deficit to date per 10-K filing is around $245M, a reasonable figure for a company founded in 2014. As for competition, I do think it's important to keep an eye on Novartis' PRC2 inhibitor MAK683. Per clinical trials gov website, DLBCL seems to be the lead indication on deck for them. However, the study design allows for evaluation in other advanced malignancies such as nasopharyngeal carcinoma ((NPC)), gastric cancer, prostate cancer or other advanced solid tumors for whom no further effective standard treatment is available. Thus, any positive data reported here would likely spark a sympathy move in shares of ORIC as well. ORIC's PRC2 inhibitor to my eyes could be its crown jewel asset out of the 3 drug candidates currently in human studies. As mentioned above, there are certain populations they could potentially pursue accelerated approval via use of biomarkers such as H3K27 trimethylation. In EGFR exon 20, I am most familiar with Cullinan Oncology's (CGEM) CLN-081, which was the recipient of co-develop deal with Taiho Oncology for $275M upfront (allows for 50/50 US share of profits). Contrast the size of the upfront payment alone to ORIC's negative EV. Core Biotech holding Blueprint Medicines (BPMC) also scooped up LNG-451 in 2021 for $250M upfront payment (this drug candidate is highly brain penetrant as well). I imagine that ORIC will have a hard time going up against such larger players including Takeda, but again showing early monotherapy activity in patients with brain metastases would still positively impact share price and sentiment which are at all-time lows. As for ORIC-533, I remain highly skeptical of the inroads they can make in the highly crowded field of multiple myeloma given the impressive efficacy of approved CAR-T treatments not to mention next-generation cell therapy pioneers behind them (see my previous piece on Arcellx). As for institutional investors of note, EcoR1 Capital owns an 8.8% stake and has been adding to its position. String of insider purchases back in Q2 of this year was also encouraging, with CEO Jacob Chacko buying over $2.6M worth of shares.
Analiz Makalesi • Oct 08

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals press release (NASDAQ:ORIC): Q2 GAAP EPS of -$0.51 beats by $0.09. Cash, cash equivalents and investments totaled $237.8 million
Analiz Makalesi • Jun 24

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Mar 08

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Nov 23

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Aug 05

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Apr 16

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Jan 01

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Hissedar Getirileri

ORICUS BiotechsUS Pazar
7D2.4%7.1%-1.5%
1Y45.8%45.3%17.8%

Getiri vs. Endüstri: ORIC geçen yıl boyunca % 45.3 oranında getiri sağlayan US Biotechs sektörüyle eşleşti.

Getiri vs Piyasa: ORIC geçen yıl % 17.8 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ORIC's price volatile compared to industry and market?
ORIC volatility
ORIC Average Weekly Movement12.1%
Biotechs Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: ORIC hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: ORIC 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2014111Jacob Chackowww.oricpharma.com

Klinik aşamada bir biyofarmasötik şirketi olan ORIC Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde kanserlerdeki direnç mekanizmalarına karşı koyacak tedavilerin keşfi ve geliştirilmesiyle ilgilenmektedir. Klinik aşamadaki ürün adayları arasında, daha önce ORIC-114 olarak bilinen, şu anda Faz 1b çalışması altında olan, epidermal büyüme faktörü reseptörü (EGFR) ekzon 20 ve insan epidermal büyüme faktörü reseptörü 2 ekzon 20'yi seçici olarak hedefleyen ve ekzon 20 ekleme mutasyonlarına karşı yüksek potensli, beyne nüfuz eden oral olarak biyoyararlanımlı geri dönüşümsüz bir inhibitör olan enozertinib; ve daha önce ORIC-944 olarak bilinen, şu anda Faz 1b çalışması altında olan prostat kanseri için polikomb baskılayıcı kompleks 2'nin allosterik bir inhibitörü olan rinzimetostat bulunmaktadır. ORIC-944'ü Nubeqa AR inhibitörü ile birlikte değerlendirmek üzere Bayer ile bir klinik çalışma işbirliği ve tedarik anlaşması; ORIC 944'ü Erleada AR inhibitörü ile birlikte değerlendirmek üzere Johnson & Johnson ile bir klinik çalışma işbirliği ve tedarik anlaşması bulunmaktadır.

ORIC Pharmaceuticals, Inc. Temel Bilgiler Özeti

ORIC Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ORIC temel i̇stati̇sti̇kler
Piyasa değeriUS$1.47b
Kazançlar(TTM)-US$140.35m
Gelir(TTM)n/a
0.0x
P/S Oranı
-10.5x
F/K Oranı

ORIC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ORIC gelir tablosu (TTM)
GelirUS$0
Gelir MaliyetiUS$0
Brüt KârUS$0
Diğer GiderlerUS$140.35m
Kazançlar-US$140.35m

Son Raporlanan Kazançlar

Jun 30, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-1.35
Brüt Marj0.00%
Net Kâr Marjı0.00%
Borç/Özkaynak Oranı0%

ORIC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/08/23 07:45
Gün Sonu Hisse Fiyatı2026/08/21 00:00
Kazançlar2026/06/30
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ORIC Pharmaceuticals, Inc. 18 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc